Akcea Expands Board of Directors with Appointment of Dr. Amber Salzman
“Amber’s experience in leading and growing successful pharmaceutical and biotechnology companies, coupled with her expertise and personal interest in rare disease, makes her a great addition to our Board,” said
Dr. Salzman is the President and CEO of Ohana Biosciences, a company with a mission to transform reproductive health through the industry’s first sperm biology platform. She previously served as the president and CEO of
Dr. Salzman received her bachelor’s degree from
“Advocating on behalf of people living with rare disease and working to bring them better treatment options, or in some cases a first-ever treatment, has been a passion of mine for many years. I have been familiar with the work being done at Akcea for some time and am honored to join the board,” said Dr. Salzman. “Akcea has made great progress in advancing its pipeline of promising therapies. I look forward to applying my experience to help the company bring more transformative treatments to people around the world who continue to live with rare diseases.”
This press release includes forward-looking statements regarding the business of Akcea Therapeutics, Inc. Any statement describing Akcea’s goals, expectations, financial or other projections, intentions or beliefs, including the commercial potential of Akcea’s drugs in development is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Akcea’s forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Akcea’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Akcea. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Akcea’s programs are described in additional detail in Akcea’s quarterly reports on Form 10-Q and annual reports on Form 10-K, which are on file with the SEC. Copies of these and other documents are available from the company.
In this press release, unless the context requires otherwise, “Ionis,” “Akcea,” “Company,” “Companies,” “we,” “our,” and “us” refers to Ionis Pharmaceuticals and/or Akcea Therapeutics.
Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals, Inc.,
Akcea Investor Contact:
Vice President of Communications and Investor Relations
Akcea Media Contact:
T: 212 253-8881
Source: Akcea Therapeutics, Inc.